ArticleCureus2025
Exploring Hesperidin Hydrogel for Pulp Capping Advancements: An In Vitro Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunomodulatory and pro-mineralizing effects of an injectable baicalein-loaded methacrylated gelatin hydrogel for vital pulp therapy.Biomaterials advances · 2026Article
- Functionalization of Photocrosslinkable GelMA Hydrogel With Metal Oxides for Direct Pulp Capping.BioMed research international · 2026Article
- Recent insights into the biological functions of hesperidin.EXCLI journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Regenerative endodontics is revolutionizing pulp preservation by utilizing bioactive materials to enhance dentinogenesis. Direct pulp capping, a widely used technique, often relies on traditional pulp-capping agents (PCAs) like Biodentine. However, limitations such as reduced long-term bioactivity highlight the need for novel alternatives. Hesperidin, a natural flavonoid with potent anti-inflammatory and angiogenic properties, has emerged as a promising candidate. This study investigates and compares the growth factor release profiles of hesperidin hydrogel and Biodentine to assess their potential in vital pulp therapy. Methods Sixty extracted human third molars were processed into dentin discs and divided into two groups: hesperidin hydrogel and Biodentine. Each group was further subdivided based on incubation durations (7, 14, and 28 days). The release of vascular endothelial growth factor (VEGF), a key regulator of angiogenesis and tissue regeneration, was quantified using enzyme-linked immunosorbent assay (ELISA). In vitro permeation studies and scanning electron microscopy (SEM) analyses were performed to assess material properties. Statistical analysis was conducted using IBM SPSS Statistics for Windows, Version 26.0 (Released 2019; IBM Corp., Armonk, NY, United States). Results Hesperidin hydrogel demonstrated a significantly higher and sustained release of VEGF compared to Biodentine across all time intervals (p < 0.0001). While Biodentine showed an initial burst release that declined over time, hesperidin hydrogel maintained stable bioactivity, indicating prolonged regenerative potential. Conclusion Hesperidin hydrogel outperforms Biodentine in sustaining VEGF release, making it a promising next-generation biomaterial for direct pulp capping. Its ability to promote angiogenesis and support long-term pulp vitality highlights its potential to revolutionize regenerative endodontics. Further in vivo studies are needed to confirm its clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.